| Name | Flufenamic acid |
| Description | Flufenamic acid (Arlef) is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. |
| In vivo | Under peak amyloid fibril formation conditions (pH 4.4), Flufenamic acid binds to wild-type transthyretin (KD1=30 nM, KD2=255 nM), V30M transthyretin (KD1=41 nM, KD2=320 nM), and L55P transthyretin (KD1=74 nM, KD2=682 nM) with high affinity and negative cooperativity (pH value 7.6), fully inhibiting fibril formation at a concentration of 10.8 μM. In Xenopus oocytes, Flufenamic acid reversibly suppresses ICl(Ca) in a dose-dependent manner, with an IC50 of 28 mM, without affecting the shape of the current-voltage curve in response to depolarizing voltage. Flufenamic acid inhibits the calcium-activated non-selective cation channels in the basolateral membrane of rat pancreatic exocrine cells activated by an inward-outward patch with an IC50 of 10 μM. The compound also inhibits currents activated by intracellular ADP-ribose in recombinant human TRPM2 (hTRPM2) channels and the CRI-G1 rat insulinoma cell line. Additionally, it reversibly inhibits (IC50=13.8 μM) DAP and phase discharge in rat suprachiasmatic neurons with similar kinetics, without significantly affecting membrane potential, spike threshold, or input resistance (P > 0.05), nor does it significantly affect the frequency and amplitude of spontaneous synaptic potentials. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 28.1 mg/mL (100 mM)
DMSO : 55 mg/mL (195.57 mM), Sonication is recommended.
|
| Keywords | Flufenamic acid | Parasite | Cl? Channels | Ca channels | AMPK | Potassium Channel | Ca2+ channels | Cyclooxygenase | Inhibitor | inhibit | COX | Chloride Channel | AMP-activated protein kinase | KcsA | Calcium Channel |
| Inhibitors Related | Kaempferol | L-Ascorbic acid | Acetaminophen | Hydroxychloroquine | Metronidazole | Nitazoxanide | Doxycycline | Benzyl benzoate | Metformin hydrochloride | Paradol | Salicylic acid | Chitosan oligosaccharide |
| Related Compound Libraries | Anti-Parasitic Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
